Table 3: Key eligibility criteria for reimbursement of sofosbuvir with peginterferon and/or ribavirin for treatment of hepatitis C virus infection, by jurisdiction
JurisdictionRestriction
Minimum fibrosis stage requiredSubstance useHIV coinfectionPrescriberDecompensated cirrhosis
Province/territory
British ColumbiaF2None listed*EligibleGeneral practitionerMay be considered
AlbertaF2None listedEligibleGeneral practitionerMay be considered
SaskatchewanF2None listed†EligibleGeneral practitionerMay be considered
ManitobaF2None listedEligibleSpecialistMay be considered
OntarioF2None listedEligibleGeneral practitionerMay be considered
QuebecNone listed‡None listedIneligible§None listedNone listed
New BrunswickF2None listedEligibleSpecialistMay be considered
Nova Scotia F2None listedEligibleGeneral practitionerMay be considered¶
Prince Edward IslandNANANANANA
Newfoundland and LabradorF2None listedEligibleGeneral practitionerNone listed
YukonF2None listedEligibleSpecialistMay be considered
Northwest TerritoriesF2None listedNone listedGeneral practitionerNone listed
NunavutF2None listedNone listedGeneral practitionerNone listed
Federal
Non-Insured Health Benefits ProgramF2None listedNone listedGeneral practitionerNone listed
Correctional Service CanadaF2**None listed††None listedNone listedNone listed

Note: NA = not available.

*No specific criteria, but exclusion criteria state: "Patients who are at high risk for non-compliance."

†However, prescriber could indicate that directly observed therapy was recommended; also, the patient consented (via signature) to understanding treatment adherence.

‡However, coauthors indicated that in practice there were no fibrosis stage restrictions.

§However, exceptions could be granted via the "patient d'exception" (exception patient) measure.

¶Source: coauthor.

**Treatment prioritized to patients with stage F3 or F4 fibrosis; treatment for those with stage F0, F1 or F2 fibrosis was reviewed on a case-by-case basis.

††Directly observed therapy required.